Key facts
- This page summarizes Adrian Rawcliffe's Form 4 filing for Adaptimmune Therapeutics PLC (ADAP).
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 17 Jan 2025, 21:15.
Adrian Rawcliffe - 17 Jan 2025 Form 4 Insider Report for Adaptimmune Therapeutics PLC (ADAP)
- Reporting relationship
- Chief Executive Officer, Director
- Issuer ticker
- ADAP
- Reported as of
- 17 Jan 2025
- Net transaction value
- -$17,773
- SEC form
- 4
- Accepted by SEC
- 17 Jan 2025, 21:15:20 UTC
- Prior SEC filing
- 15 Jan 2025
- Next SEC filing
- 20 Feb 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ Adrian George Rawcliffe
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Adrian Rawcliffe filed Form 4 for Adaptimmune Therapeutics PLC (ADAP) on 17 Jan 2025.
Change
- Previous filing in this sequence was filed on 15 Jan 2025.
- Current net transaction value: -$17,773.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
ADAP
transaction
American Depositary Shares representing Ordinary Shares
Sale
- Transaction value
- $17,773
- Shares
- -30,601
- Change %
- -41%
- Price
- $0.5808
- Shares after
- 44,327
- Date
- 17 Jan 2025
- Ownership
- Direct
- Footnotes
- F1, F2, F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
Each American Depositary Share ("ADS") represents six ordinary shares, nominal value GBP 0.001 per ordinary share, of the Issuer. The ADSs were obtained from the exercise of approximately 25% of an RSU-style share option covering ordinary shares of the Issuer granted on January 17, 2023 and which have vested. Once vested, the RSU-style options must be exercised within a restricted period or they are forfeited. The exercise of the portion of these RSU-style share options and the sale reported in this Form 4 were effected pursuant to a Sell to Cover exercise implemented automatically in accordance with the Issuer's option plan, under which sufficient ADSs were sold by the Issuer to satisfy the Reporting Person's tax withholding obligations and associated sale costs. The residual ADSs are held by the Reporting Person.
Footnote F2
The price reported in Column 4 is a weighted average price. These ADSs were sold in multiple transactions at prices ranging from $0.5797 to $0.589, inclusive. Upon request, the Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission full information regarding the ADSs sold at each separate price within the range set forth in this footnote.
Footnote F3
The ADSs reported in this Column 5 represent solely those residual ADSs held by the Reporting Person which result from the Sell to Cover exercise transaction reported on this Form 4. Additionally, the Reporting Person holds 350,900 ADSs and RSU-style options and other options covering an aggregate of 34,439,286 ordinary shares of the Issuer.